Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aeterna Zentaris, an oncology drug development company, has reported revenues of $7.39m for the first quarter ended 31 March 2011, compared to $6.42m for the same period in 2010.
Subscribe to our email newsletter
The increase in revenues is related to comparative higher-than-normal deliveries of Cetrotide to certain customers, as well as to the comparative strengthening of the euro against the US dollar.
Aeterna Zentaris has reported a net loss of $10.06m, or $0.12 loss per diluted share, compared to net loss of $5.75m or $0.09 per diluted share, for the same period last year.
Loss from operations were $7.29m, as compared to $7.4m for the same period prior year.
Aeterna Zentaris president and CEO Juergen Engel said the quarter was marked mainly by the agreement with Yakult for the lead anticancer compound, perifosine, for the Japanese market.
"We will now focus on pursuing the development of our main value drivers with the completion of the Phase 3 trial with perifosine in refractory advanced colorectal cancer by year-end and the progression of the Phase 3 trial in multiple myeloma, as well as the initiation of a pivotal trial with AEZS-108 in endometrial cancer," Engel said.